InMode (INMD) Competitors $14.83 -0.51 (-3.32%) Closing price 04:00 PM EasternExtended Trading$15.01 +0.18 (+1.21%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMD vs. SLNO, TMDX, NVST, LIVN, WRBY, INSP, LQDA, LMAT, PRCT, and AORTShould you be buying InMode stock or one of its competitors? The main competitors of InMode include Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), and Artivion (AORT). These companies are all part of the "medical equipment" industry. InMode vs. Its Competitors Soleno Therapeutics TransMedics Group Envista LivaNova Warby Parker Inspire Medical Systems Liquidia Technologies LeMaitre Vascular PROCEPT BioRobotics Artivion InMode (NASDAQ:INMD) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Is INMD or SLNO more profitable? InMode has a net margin of 44.50% compared to Soleno Therapeutics' net margin of 0.00%. InMode's return on equity of 18.38% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InMode44.50% 18.38% 16.35% Soleno Therapeutics N/A -73.74%-56.67% Does the media refer more to INMD or SLNO? In the previous week, Soleno Therapeutics had 34 more articles in the media than InMode. MarketBeat recorded 40 mentions for Soleno Therapeutics and 6 mentions for InMode. InMode's average media sentiment score of 1.46 beat Soleno Therapeutics' score of 0.52 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive Do insiders and institutionals believe in INMD or SLNO? 68.0% of InMode shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, INMD or SLNO? InMode has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.72, indicating that its stock price is 372% less volatile than the S&P 500. Do analysts prefer INMD or SLNO? InMode presently has a consensus price target of $18.04, indicating a potential upside of 21.66%. Soleno Therapeutics has a consensus price target of $115.09, indicating a potential upside of 114.64%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than InMode.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMode 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has better earnings and valuation, INMD or SLNO? InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInMode$394.82M2.37$181.27M$2.476.00Soleno TherapeuticsN/AN/A-$175.85M-$4.14-12.95 SummaryInMode beats Soleno Therapeutics on 10 of the 16 factors compared between the two stocks. Get InMode News Delivered to You Automatically Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMD vs. The Competition Export to ExcelMetricInModeMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$969.63M$10.93B$5.86B$10.15BDividend YieldN/A1.84%5.68%4.59%P/E Ratio6.0021.1374.5225.93Price / Sales2.3731.03536.78122.58Price / Cash8.4124.8137.5660.44Price / Book1.473.5212.166.29Net Income$181.27M$210.50M$3.28B$270.77M7 Day Performance-1.00%-0.18%0.98%3.36%1 Month Performance4.29%3.91%7.20%6.41%1 Year Performance-11.46%-10.02%63.06%28.26% InMode Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMDInMode3.1199 of 5 stars$14.83-3.3%$18.04+21.7%-9.2%$969.63M$394.82M6.00480Positive NewsSLNOSoleno Therapeutics4.4347 of 5 stars$72.30+3.6%$115.09+59.2%+16.8%$3.84BN/A-17.4630Trending NewsAnalyst UpgradeShort Interest ↑Analyst RevisionTMDXTransMedics Group2.8578 of 5 stars$105.58+1.5%$122.11+15.7%-18.6%$3.60B$441.54M54.70210NVSTEnvista3.9232 of 5 stars$21.14-0.8%$20.92-1.0%+22.5%$3.51B$2.51B66.0512,300Positive NewsLIVNLivaNova2.9039 of 5 stars$58.32+0.6%$59.71+2.4%+20.8%$3.18B$1.25B-14.992,900Positive NewsWRBYWarby Parker1.6853 of 5 stars$26.74+2.8%$24.06-10.0%+96.3%$2.81B$771.32M-382.003,780Positive NewsInsider TradeINSPInspire Medical Systems4.9005 of 5 stars$83.51-3.4%$164.50+97.0%-60.0%$2.47B$802.80M48.271,246Positive NewsLQDALiquidia Technologies3.7 of 5 stars$27.98-3.0%$32.11+14.8%+166.0%$2.41B$14M-16.4650Positive NewsLMATLeMaitre Vascular3.0875 of 5 stars$97.07-0.4%$97.60+0.5%+8.6%$2.20B$219.86M47.12490Positive NewsPRCTPROCEPT BioRobotics3.2237 of 5 stars$38.92-4.3%$73.22+88.1%-50.5%$2.17B$274.95M-25.11430Positive NewsAORTArtivion3.0785 of 5 stars$43.34-0.3%$40.63-6.2%+73.7%$2.04B$388.54M-103.191,600Positive News Related Companies and Tools Related Companies SLNO Alternatives TMDX Alternatives NVST Alternatives LIVN Alternatives WRBY Alternatives INSP Alternatives LQDA Alternatives LMAT Alternatives PRCT Alternatives AORT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMD) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMode Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMode With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
